Belhaven Biopharma News and Resources

Belhaven Biopharma has announced the launch of a new clinical study designed to evaluate the commercial dose of Nasdepi, an intranasal epinephrine product aimed at treating severe allergic reactions. The company has secured $11 million in funding through its fourth